The combined annual global market size of the indications we are targeting is over US$110 billion, which is derived from the total addressable market for the treatment of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and GAD. Success in the clinical development programmes will not only provide benefit to patients suffering from untreated medical conditions, but also significant economic potential for shareholders.
ASX : IHL
The potential is limitless
Incannex are global leaders in the development of novel medicinal cannabinoid compounds and psychedelic therapies.
ASX : IHL
The potential is limitless
Incannex are global leaders in the development of novel medicinal cannabinoid compounds and psychedelic therapies.
ASX : IHL
Boundless medical potential
Undertaking six clinical programs targeting conditions for patients with unmet medical needs.
ASX : IHL
Boundless medical potential
Undertaking six clinical programs targeting conditions for patients with unmet medical needs.
ASX : IHL
Unrivalled economic potential
The combined annual global market size of the indications we are targeting is over US$110 billion.
ASX : IHL
Unrivalled economic potential
The combined annual global market size of the indications we are targeting is over US$110 billion.


Clinical Development Pathway
Incannex is a cannabinoid and psychedelic compound medicine development company undertaking six clinical programs guided by our medical advisory board. These 6 programs are targeting conditions for patients with unmet medical needs. This means we have the ability to help billions of people around the planet. The potential is limitless.
US$110 billion potential.


News
Subscribe
Stay up to date with Incannex’s research and development program.